In Vivo Pharmacokinetics Studies for Biologics
ProBio's in vivo pharmacokinetic (PK) studies help characterize drug exposure, establish PK-PD relationships, and optimize dosing strategies. Using mouse, rat, and non-human primate (NHP) models, we provide integrated PK, receptor occupancy (RO), ADA, and tissue distribution analyses to support confident drug development decisions.
In Vivo PK Studies Supporting Faster Drug Development Decisions
Complete Platform
Comprehensive PK platform to generate robust in vivo exposure data, supporting mAbs, bsAbs, ADCs, CGTs, proteins, and vaccines.
Early PK for Drug Discovery
We enable access to high-quality, cost-effective Non Human Primate (NHP) PK studies that are practical and accessible at the discovery stage.
One-Stop Solution
One-stop PK, bioanalytical, immunogenicity, and biodistribution capabilities simplify outsourcing and avoid issues with multiple vendors.
PK Study and Bioanalysis Method in As Fast As 6 Weeks
Case Studies
Accelerating Lead Candidate Selection with Early-Stage NHP Pharmacokinetic Screening.
Extending VHH Antibody Half-Life Through Fc and Albumin Fusion Strategies.
Resources
BROCHURE
Biologics Discovery Services Brochure
Tailored discovery strategies for diverse biologics modalities, designed to enhance success rates.
FLYER
In Vivo Pharmacology
Solutions including efficacy, biological Activity, DMPK, bioanalysis and toxicity.
WHITE
PAPER
Discovery of Functional Antibody Leads at Early Stage of Lead Screening
Solutions for antibody discovery platforms to overcome the limitations and improve efficiency of lead discovery.
FLYER
Powerdoma™: An Upgraded Hybridoma Platform
Making NHP PK studies more accessible for drug discovery.
Frequently Asked Questions